Live tape
Top 8, mentions 7d14,336GOOGL2,871 mentions▲ +0.04NVDA2,215 mentions▲ +0.05AMD1,940 mentions▲ +0.08QQQ1,751 mentions▲ +0.05AAPL1,729 mentions▲ +0.05SPY1,560 mentions▲ +0.06TSLA1,164 mentions▲ +0.06SPCX1,106 mentions▲ +0.05

Equity · Healthcare

JBIO

NASDAQ

Jade Biosciences (JBIO)

21 USD +2.56% vs prior close
Jade Biosciences, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for JBIO to draw a line in its place.

Track this symbol on TradingView
Market cap
1.3B USD
P/E (TTM)
2.5
EPS, diluted, year to Dec 2025
−3.19 USD
52-week range
6.85 USD – 26.83 USD
Avg volume
293.9K

as of Jul 17, 2026

Have Jade Biosciences (JBIO) insiders bought or sold shares recently?

JBIO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 12 February 2026.

Form 4

Have Jade Biosciences (JBIO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
12 Feb 2026Dahms Bradford D.Chief Financial OfficerAward37,813
12 Feb 2026Balta ElizabethSee RemarksAward28,125
12 Feb 2026Frohlich TomChief Executive OfficerAward78,750
12 Feb 2026King Andrew JamesSee RemarksAward41,250
06 Oct 2025Fairmount Funds Management LLCAward2,188,17320.0M USD

Which funds hold Jade Biosciences (JBIO)?

11 of the 45 institutional funds we track reported a Jade Biosciences position for the quarter ended 30 Jun 2026 — a combined 95.9M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Jade Biosciences (JBIO)?
FundPositionSharesValueShares q/q
Baker Bros. AdvisorsTrimmed1,230,42627.3M USD−25.0%
Citadel AdvisorsAdded929,40720.7M USD+577.3%
Balyasny Asset ManagementAdded878,72619.5M USD+118.3%
Marshall WaceTrimmed585,76113.0M USD−38.0%
Millennium ManagementAdded314,5487.0M USD+96.5%
Point72 Asset ManagementTrimmed167,2043.7M USD−36.7%
Renaissance TechnologiesTrimmed73,5911.6M USD−45.5%
D. E. Shaw & Co.New position51,4941.1M USD
Two Sigma InvestmentsAdded45,3611.0M USD+148.5%
Man GroupNew position26,123580K USD

Showing the 10 largest of 11 reported positions. The figures above count all of them.

What has been filed or recorded for Jade Biosciences (JBIO)?

The filings we hold for Jade Biosciences, newest first: 8 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Jade Biosciences (JBIO)?
And
14 Oct 2026Fails to deliverShares failed to deliver3,391 shares46K USD notional · 0.005% of shares out
06 Oct 2026Fails to deliverShares failed to deliver1,714 shares24K USD notional · 0.003% of shares out
05 Oct 2026Fails to deliverShares failed to deliver2,734 shares39K USD notional · 0.004% of shares out
02 Oct 2026Fails to deliverShares failed to deliver747 shares10K USD notional · 0.001% of shares out
01 Oct 2026Fails to deliverShares failed to deliver1,662 shares23K USD notional · 0.003% of shares out
30 Sep 2026Fails to deliverShares failed to deliver838 shares12K USD notional · 0.001% of shares out
28 Sep 2026Fails to deliverShares failed to deliver3,244 shares47K USD notional · 0.005% of shares out
25 Sep 2026Fails to deliverShares failed to deliver3,473 shares51K USD notional · 0.005% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.76 USD
30 Jun 2026FinancialsTotal assets472.1M USDat period end
30 Jun 2026FinancialsTotal equity439.9M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.57 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −3.19 USD
31 Dec 2025FinancialsNet income−127.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.19 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.48 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.86 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −12.10 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −14.89 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −5.16 USD

Jade Biosciences (JBIO): frequently asked questions

From live data
1.3B

What is Jade Biosciences’ market cap?

Jade Biosciences is worth 1.3B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

2.5

What is Jade Biosciences’ P/E ratio?

Jade Biosciences has a price-to-earnings ratio of 2.5, as of 17 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

Have Jade Biosciences insiders bought or sold shares recently?

No Jade Biosciences insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 12 Feb 2026 (SEC Form 4). See Insiders

11 of 45

Which funds own Jade Biosciences?

11 of the 45 funds we track reported a Jade Biosciences position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Citadel Advisors and Balyasny Asset Management. See Funds

−0.76

When did Jade Biosciences last report earnings?

Jade Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.76 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings